Pivotal Therapeutics Inc

http://www.pivotaltherapeutics.us

01.04.2015 – 22:18
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the United Stated Patent and Trademark Office (USPTO) has ...
mehr
17.12.2014 – 13:35
VASCAZEN® POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced that on December 16, 2014 the French FDA in Paris (ANSM: Agence Nationale de la Sécurité du Médicament - French ...
mehr
08.10.2014 – 21:03
Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published ...
mehr
07.10.2014 – 13:01
Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN® and Statin Therapy
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published ...
mehr
10.09.2014 – 21:31
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today the publication of results of a prospective randomized ...
mehr
03.09.2014 – 21:01
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today that the cardio-protective effects of Pivotal's unique ...
mehr
19.08.2014 – 18:24
Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today that an article entitled, "Redox-sensitive induction of Src/PI3-kinase/Akt and MAPKs pathways activate eNOS in ...
mehr
04.03.2014 – 15:44
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total ...
mehr
29.01.2014 – 19:09
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA:DHA Formulation
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced that it received a Notice of Allowance for U.S. Application Serial Number US2012/025014 from the United States Patent and Trademark Office ...
mehr

07.05.2013 – 17:55
Pivotal Therapeutics VASCAZEN®-REVEAL Trial Meets Primary and Secondary Endpoints - VASCAZEN® Shows 121% Correction of an Omega-3 Deficiency (p< 0.0001) with a Concomittant 48% Reduction in Triglycerides (p<0.0005)
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, presented positive, statistically significant, top-line results from its VASCAZEN(R)-REVEAL trial for ...
mehr
02.05.2013 – 18:40
Pivotal's Founder and Chairman Dr. George Jackowski receives Queen Elizabeth II Diamond Jubilee Medal
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that Dr. George Jackowski, Founder, Chairman and Chief Scientific Officer was awarded the Queen Elizabeth II Diamond Jubilee Medal ...
mehr
04.09.2012 – 19:33
Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular disease and overall health, is pleased to announce that the company received a positive response to its lead product VASCAZEN(TM) at the European Society of ...
mehr
23.08.2012 – 21:07
Pivotal Therapeutics Exhibiting at European Society of Cardiology Congress 2012
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular disease and overall health, is pleased to announce that the company will be exhibiting at the European Society of Cardiology (ESC) Congress 2012 in Munich, Germany August 25-29, 2012, Hall A2 Booth #B440. The ESC ...
mehr
09.08.2012 – 22:47
Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN? Unique Formulation
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company with a focus on cardiovascular health, is pleased to announce that data from a scientific study related to the company's product VASCAZEN(TM) concluded that highly purified Eicosapentaenoic ...
mehr